(Applicant's Description) The University of Pittsburgh Cancer Institute (UPCI) is a multidisciplinary cancer research center, with programs in basic research, translational research and clinical investigations, prevention and control, early diagnosis and treatment, and behavioral medicine research. In addition, it has responsibility of cancer education and clinical care. The UPCI is comprised of faculty form the University of Pittsburgh and Carnegie Mellon University and utilizes the clinical facilities of the University of Pittsburgh and Medical Center Health System plus two University affiliated hospitals (Children's Hospital of Pittsburgh and Magee Women's Hospital). The UPCI has established programs in: molecular and cellular oncology, molecular therapeutic and drug discovery, immunology, molecular virology, lung cancer, prostate and urologic cancers, head and neck cancer, biological therapeutics, cancer epidemiology, prevention and control, and behavioral medicine and oncology. To assist its research efforts, the UPCI maintains shared facilities including: Biostatistics Facility, Clinical Research Support Services, Immunologic Monitoring Laboratory, Cellular Products Laboratory, Hybridoma Facility, Flow Cytometry Facility, DNA Sequencing Facility, Peptide Synthesis Facility, Animal Facility, Glassware Facility, Oligonucleotide Facility, and Cell and Tissue Imaging Facility. This application requests continued cancer center support grant (CCSG) funding for the University of Pittsburgh Cancer Institute's program for years 12-16.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-12
Application #
2883844
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1988-08-01
Project End
2004-07-30
Budget Start
1999-09-20
Budget End
2000-07-31
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications